What Researchers Did
Researchers conducted an open-label prospective interventional study to investigate how hyperbaric oxygen therapy affects gut microbiota and inflammation in 20 Crohn's disease patients.
What They Found
They found that hyperbaric oxygen therapy significantly reduced C-reactive protein from 80.79 mg/L to 33.32 mg/L (P=0.004) and the Crohn's Disease Activity Index from 274.87 to 221.54 (P=0.044). The therapy also improved microbial diversity, decreasing *Escherichia* while increasing *Bifidobacterium* and *Clostridium XIVa*, and was safe and well-tolerated.
What This Means for Canadian Patients
This research suggests that hyperbaric oxygen therapy could potentially offer a new treatment option for Canadian Crohn's disease patients by modulating gut microbiota and reducing inflammation. Such a therapy might help manage symptoms and improve overall well-being for those seeking alternative or complementary approaches.
Canadian Relevance
This study has no direct Canadian connection as it was not conducted in Canada or by Canadian researchers.
Study Limitations
A significant limitation of this study is its small sample size of only 10 patients per group and its open-label design.